1 eatment with infliximab (0.36; P = .0005) or 5-aminosalicylic acid (0.44; P < .0001) were associated

2                                          The 5-aminosalicylic acid (5-ASA) agents and oral steroids r

3                    We recently reported that 5-aminosalicylic acid (5-ASA) inhibits TNFalpha-regulate

4  IL-1-mediated COX-2 gene expression whereas 5-aminosalicylic acid (5-ASA) or indomethacin had no eff

5 NSAIDs) 4-aminophenylacetic acid (4-APAA) or 5-aminosalicylic acid (5-ASA) with peptides, including a

6  and its metabolites, sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA), on components of angiogen

7 atory drugs (OR, 0.1; 95% CI: 0.03-0.5), and 5-aminosalicylic acid agents (OR, 0.4; 95% CI: 0.2-0.9),

8 f sulfasalazine (SSZ) with its two moieties, 5-aminosalicylic acid (ASA) and sulfapyridine (SP), in p

9 er, and smoking and drug history (mesalamine 5-aminosalicylic acid, azathioprine, and folate).

10                             Corticosteroids, 5-aminosalicylic acid derivatives, immunomodulators, and

11    Treatments for ulcerative colitis include 5-aminosalicylic acid drugs, steroids, and immunosuppres

12             Two lanthanide complexes, namely 5-aminosalicylic acid ethylenediaminetetraacetate europi

13 conventional therapy, once daily therapy for 5-aminosalicylic acid is generally sufficient.

14                           Furthermore, a new 5-aminosalicylic acid (mesalamine MMX) has been released

15                               Derivatives of 5-aminosalicylic acid (mesalamine) represent a mainstay

16 ssification; and use of sulfasalazine, other 5-aminosalicylic acid preparations, prednisone, cyclospo

17                 Surveillance colonoscopy and 5-aminosalicylic acid therapy may mitigate cancer risk,

18 e sensitization of Eu3+ is accomplished with 5-aminosalicylic acid, which provides energy transfer fo